BCR-ABL mutations in chronic myeloid leukemia - Not only detection

Leukemia and Lymphoma

Volumn 49, Issue 8, 2008, Pages 1620-1622

  Polakova, Katerina Machova ^a   Zmekova, Vaclava ^a   Rulcova, Jana ^a   Klamova, Hana ^a   Zemanova, Zuzana ^a   Moravcova, Jana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; DASATINIB; IMATINIB; INTERFERON;

ADULT; ARTICLE; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; LEUKEMIA RELAPSE; MALE; MOLECULAR CLONING; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT DURATION;

FUSION PROTEINS, BCR-ABL; HUMANS; KINETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL;

EID: 51349094373     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802105074     Document Type: Article

References (7)

1. Hughes, T., Deininger, M., Hochhaus, A., Brandford, S., Radich, J. Kaeda, J. et al. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108, pp. 28-37.
2. Rulcova, J., Zmekova, V., Zemanova, Z., Klamova, H. and Moravcova, J. (2007) The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res, 31, pp. 483-491.
3. Soverini, S., Martinelli, G., Colarossi, S., Gnani, A., Gastagnetti, F. Rosti, G. et al. (2006) Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chomosome-positive leukemia. J Clin Oncol, 24, pp. e51-e52.
4. Khorashad, J. S., Milojkovic, D., Mehta, P., Anand, M., Ghorashian, S. Reid, A. G. et al. (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood, 111, pp. 2378-2381.
5. Kantarjian, H., Schiffer, Ch, Jones, D. and Cortes, J. (2008) Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods. Blood, 111, pp. 1774-1780.
6. Ernst, T., Erben, P., Muller, M. C., Paschka, P., Schenk, T. Hoffman, J. et al. (2008) Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica, 93, pp. 186-192.
7. Baccarani, M., Saglio, G., Goldman, J., Hochaus, A., Simonsson, B. Appelbaum, F. et al. (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, pp. 1809-1820.